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Abstract 
Background: Chagas disease is a protozoan infection caused by Trypanosoma cruzi. The disease has a chronic course 
in which 20–30% of the patients would develop progressive damage to the cardiovascular system and the gastro‑
intestinal tube. We are still unable to predict who will develop end‑organ damage but there are some acquired and 
genetic risk factors already known.
Results: We reviewed data from 833 patients with serologically confirmed Chagas disease in this retrospective 
study. Patients were classified as siblings or non‑siblings (controls) and the results of pre‑treatment blood PCR assay, 
end‑organ damage (cardiac and/or gastrointestinal), and the presence of delayed type hypersensitivity (DTH) skin 
involvement in patients treated with benznidazole were analyzed. Siblings were grouped by family and we randomly 
generated groups of 2 or 3 persons with the remaining controls. We classified the results of each variable as con‑
cordant or discordant and compared the concordance in these results among the sibling groups with that among 
control groups. We identified 71 groups of siblings and randomly generated 299 groups of non‑related patients. 
Pre‑treatment blood PCR concordance was significantly higher (19%) among siblings compared to controls (P = 0.02), 
probably due to a higher frequency in pre‑treatment positive results. No other statistically significant differences were 
found.
Conclusions: A significant difference was found in the concordance of pre‑treatment blood PCR for T. cruzi among 
siblings compared to non‑related controls.
Keywords: Chagas disease, Siblings, Brotherhood, Cardiomyopathy, Gastrointestinal disease, Delayed type 
hypersensitivity
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Background
Chagas disease is caused by the protozoan hemoflagellate 
T. cruzi and is estimated to affect more than 6–13 mil-
lion people worldwide. Socioeconomic development and 
migrant flows have caused the disease to change from a 
rural vector-borne disease endemic to Latin America to 
a global disease with different mechanisms of transmis-
sion (mother-to-child transmission, tissue and organ 
transplantation, blood transfusion, and oral transmission 
through infected food). After the initial, acute phase, 
Chagas disease has a chronic course in which most 
patients remain asymptomatic for life, the so-called inde-
terminate phase of the disease. Over years to decades, 
about 20–30% of these patients progress to the determi-
nate phase of the disease, characterized by cardiac and/or 
gastrointestinal manifestations [1, 2].
In chronic Chagas disease, there is a consensus about 
the recommendation of treating patients younger than 
18 years-old, women at childbearing age, and people 
at risk or actually suffering a reactivation of the disease 
(i.e. when receiving immunosuppressant drugs), on the 
basis of different studies [3–5]. The BENEFIT study has 
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recently showed no improvement when there is estab-
lished chronic chagasic cardiomyopathy [6]. The corner-
stone of the treatment against T. cruzi is benznidazole. 
The main drawback of benznidazole is its toxicity, which 
appears in 40–70% of the patients leading to discontinua-
tion of treatment in 12–18% of them [7–9].
There is increasing evidence on predisposing fac-
tors to organ damage and to treatment-related toxic-
ity in patients with chronic Chagas disease [10–12]. 
Some of this evidence shows a central role of the host’s 
genetic background in regulating the immune response 
against the parasite, which leads to tissue damage when 
it is improperly regulated [13]. We hypothesized that 
this genetic background could make disease progression 
and toxicity outcomes more similar among siblings than 
among non-related patients and conducted a retrospec-
tive review to compare these variables between both 
groups.
Results
From the 833 patients with a diagnosis of Chagas disease 
in our database, we identified 153 siblings in 71 groups. 
With the remainder of the database, 299 groups of non-
siblings were randomly generated. The demographic 
and clinical characteristics of the full database and the 
sibling groups are shown in Table 1. Ninety-five percent 
Table 1 Demographic characteristics of the siblings grouped in 71 phratries, the remaining controls and the full cohort
*P < 0.05 (statistically significant differences)
Abbreviations: n, number of patients; PCR, polymerase chain reaction
Variable Siblings (n = 53) (71 
groups) (%)
Control (n = 685) (299 
groups) (%)
P-value siblings vs 
controls
Cohort (n = 833) (%) P‑value 
siblings vs 
cohort
Country of origin
 Argentina 3 (1.96) 15 (2.18) 0.865 18 (2.16) 0.875
 Bolivia 144 (94.11) 640 (93.43) 0.757 784 (94.11) 1.000
 Brazil 0 2 (0.29) 0.505 2 (0.24) 0.544
 Chile 0 1 (0.14) 0.141 1 (0.12) 0.668
 Colombia 0 2 (0.29) 0.505 2 (0.24) 0.544
 Ecuador 1 (0.65) 4 (0.58) 0.919 5 (0.60) 0.942
 El Salvador 0 2 (0.29) 0.505 2 (0.24) 0.544
 Honduras 3 (1.96) 5 (0.72) 0.152 8 (0.90) 0.240
 Paraguay 0 6 (0.87) 0.247 6 (0.70) 0.299
 Spain 2 (1.30) 1 (0.14) 0.028* 3 (0.36) 0.132
 Venezuela 0 2 (0.29) 0.505 2 (0.24) 0.544
Sex
 Female 104 (67.97) 457 (66.71) 0.765 561 (67.34) 0.878
 Male 49 (32.02) 223 (32.55) 0.899 272 (32.65) 0.878
Mean age (years) 42 44 44
Pre‑treatment PCR 112 (73.20) 495 (73.26) 0.988 607 (72.86) 0.931
 Positive 45 (40.17) 200 (29.19) 0.008* 245 (29.41) 0.008*
Kushnir 142 (92.81) 637 (93.00) 0.934 779 (93.51) 0.749
 K 0 119/142 (83.80) 539/637 (84.61) 0.803 658/779 (84.44) 0.841
 K 1 18/142 (12.67) 77/637 (12.08) 0.840 95/779 (12.19) 0.868
 K 2 2/142 (1.40) 12/637 (1.88) 0.686 14/779 (1.79) 0.734
 K 3 3/142 (2.11) 9/637 (1.41) 0.525 12/779 (1.54) 0.609
Barium enema 128 (83.66) 553 (80.72) 0.399 681 (81.75) 0.572
 Pathologic 24 (18.75) 119 (17.37) 0.685 143 (21.00) 0.527
Esophagogram 109 (71.24) 421 (61.45) 0.023* 530 (63.62) 0.069
 Pathologic 6/109 (5.55) 26/421 (3.79) 0.322 32/530 (6.03) 0.818
Treatment 100 (65.35) 441 (64.37) 0.819 541 (64.94) 0.922
 Benznidazole 91/100 (91) 409/441 (93) 0.392 500/541 (92.00) 0.678
 Posaconazole 9/100 (9) 32/441 (7.2) 0.445 41/541 (7.57) 0.544
Rash (benznidazole) 16/91 (17.58) 88/409 (21.51) 0.279 104/500 (20.80) 0.3628
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of the patients were born in Bolivia. There was one case 
in which one brother was born in Bolivia and the other 
in Argentina. In another group, both brother and sister 
were born in Spain. Sixty-eight percent of the patients 
were female. Pre-treatment PCR assay was performed 
in a similar proportion in all the groups, but it was posi-
tive in a higher proportion among the sibling population 
than in the general and control population (40 vs 29%, 
Z = 2.64 and Z = 2.65, respectively; both P = 0.008). The 
proportion of patients to whom an esophagogram was 
performed was different (71% in the sibling group vs 
61% in the control (Z = 2.27, P = 0.02) and 63% (Z = 1.81, 
P = 0.06) in the full database, although the rate of patho-
logical esophagograms was similar in all groups (4–6%, 
without statistical significance).
The results of the concordance analysis of the valid data 
are summarized in Table 2. Incomplete data from one or 
more of the members of a given group led to the loss of a 
notable number of groups in the analysis of each variable. 
We found a significant difference in the proportion of 
concordant results of the pre-treatment PCR assay (69% 
of the sibling groups vs 50% of the controls; χ2 = 4.73, 
df = 1, P = 0.02), and this difference was still significant 
after splitting the concordant groups into “all positive” 
and “all negative” of both siblings and controls, due to the 
difference in the “all positive”. Results of barium enema 
were more concordant among the siblings than among 
the controls, but the difference did not reach statistical 
significance (75 vs 62%, χ2 = 2.90, df = 1, P = 0.08), with 
similar rates of available data in both groups (67.60 vs 
73.91%, χ2 = 1.15, df = 1, P = 0.28). The difference in con-
cordance rates of DTH events related to benznidazole 
was very small between siblings and controls (62.5 vs 
60.15%, χ2 = 0.06, df = 1, P = 0.80). In the analysis of the 
positive vs negative concordance in DTH, a substantial 
difference was found both in siblings and controls with 
more “all negative” groups among siblings than among 
controls (15.62 vs 3.91%, P = 0.04, OR = 3.95, 95% CI: 
0.85–18.33), but none of these comparisons reached 
statistical significance. Cardiovascular evaluation was 
similar in both groups, mostly with negative results, 
resulting in high concordance rates (76.67% in the sib-
lings and 73.4% in the controls, χ2 = 0.27, df = 1, P = 0.59). 
When considering esophagogram results the rates of 
concordant results were similar (89.47 vs 92%, P = 0.74, 
OR = 0.73, 95% CI: 0.19–3.41), despite a difference in the 
available data from relatives and non-relatives (53.52 vs 
42.14%, respectively, χ2 = 3.01, df = 1, P = 0.08).
Discussion
In our retrospective study we found a statistical differ-
ence in the rate of concordance of pre-treatment PCR, 
but not in the remaining variables (Kuschnir status, 
result of the esophagogram and barium enema, and the 
presence of DTH after benznidazole use).
In the studied data, there was a near 2:1 ratio of female 
to male patients, which may reflect patterns of migra-
tion and approach to healthcare, probably under-repre-
senting male involvement in the endemic countries. The 
vast majority of patients were Bolivian, so the results are 
applicable mainly to this population. There was a signifi-
cant difference in the country of origin only in the case of 
Spanish patients, which represented documented cases 
of vertical transmission. They were so small in number 
that the likely effect on the global analysis is negligible (2 
in the sibling groups and 1 in the controls, P = 0.02).
PCR
The main and only significant difference was found in 
the concordance of pre-treatment PCR. Nevertheless, 
the significantly higher positive result in pre-treatment 
blood PCR test among the patients included in the sib-
ling groups as compared to the controls (40% vs 29%, 
P = 0.008) may have biased the results; it must be noted 
that when splitting the concordant groups on the basis 
of positive or negative results, the biggest difference was 
seen between the “all positive” sibling and control groups, 
with a narrower difference between the “all negatives”.
Taking into account these limitations, the difference in 
the concordance of PCR results between siblings points 
to the presence of genetically determined mechanisms 
involved in the relationship between the host and infect-
ing T. cruzi. There is growing evidence for the influence 
of genetic elements on parasite control by the immune 
system in patients with chronic Chagas disease, but these 
studies are focused on end-organ damage rather than 
on the detection of the relationship of PCR assays and 
persistent parasitaemia because of the limitations of the 
technique. It is known that parasitaemia oscillates dur-
ing the natural history of the disease, and a positive blood 
PCR result only indicates that in the moment of the 
sampling, there was parasitic DNA in the bloodstream. 
Furthermore, some acquired conditions are known to 
modify the results of PCR assays in patients with Chagas 
disease, such as co-infection with helminths, infection 
with human immunodeficiency virus, immunosuppres-
sion and pregnancy [14–17]. In the last 15 years a strong 
effort has been made in validation and standardization 
of these techniques, reaching a sensitivity of 60–90% 
for the best performing methods, with a specificity of 
100% [18, 19]. In our study, pre-treatment PCR was per-
formed in 73% of our patients. It was positive in 29.41% 
of the patients, the expected sensibility using available 
assays in a clinical setting. The difference between the 
best performing methods and the results obtained in our 
cohort can be explained by the different sample volume, 
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conditions of conservation of the sample, the methods 
used to isolate DNA, the sequences and the reagents 
used, and the thermo-cycling conditions [18].
Cardiomyopathy
We did not find a significant relationship between kin-
ship and the presence of chagasic cardiomyopathy. The 
immune response regulation against the parasites infest-
ing the myocardium seems to be of central importance in 
the development of tissue damage. In patients with cardi-
omyopathy, the upregulation of this response leads to the 
deployment of a high-grade, harmful inflammation [20, 
21]. Familial aggregation of chagasic cardiomyopathy in 
a cohort of patients with serologically confirmed Chagas 
disease including 247 patients with cardiomyopathy and 
345 controls suggests a genetic component in the regula-
tion of this immune response [22]. Different HLA class I 
and II polymorphisms have been identified as protective 
or predisposing factors to the development of chagasic 
cardiomyopathy in different Latin-American popula-
tions (i.e. a higher frequency of chagasic cardiomyopathy 
with DRB1∗01, DRB1∗08, and DQB1∗0501 in Venezue-
lan patients, and with HLA-DQ1 in Brazilian patients). 
Mutations of the killer cell immunoglobulin-like recep-
tor genes, TNF-α and caspase pathways have also been 
related to cardiac involvement [23–27].
As cardiovascular disease (sudden death, end-stage 
cardiac failure and thromboembolism) is the leading 
cause of death in patients with Chagas disease, a cardiac 
screening should be performed in all patients [11, 28]. 
Despite that aim, in our cohort the missing evaluations 
invalidated 15.5% of the sibling groups (only 0.67% of the 
control groups). It is also relevant that cardiac abnormali-
ties have a low prevalence in our cohort (121 patients, 
15.56%, are rated in a Kushnir stage other than 0), and 
notably most concordant groups in both siblings and 
controls are due to “all negative” concordance thus mak-
ing unapparent the familiar aggregation of cardiomyopa-
thy reported in the aforementioned studies.
Gastrointestinal involvement
When considering barium enema, concordance was 
higher among the siblings than among the controls, but 
the difference did not reach statistical significance (75 vs 
62%, P = 0.08). As in the case of the cardiac evaluation, 
there are few “all positive” groups. Regarding the esoph-
agogram, the rates of concordant results were similar 
(89.47 vs 92.00%), despite a difference in the available 
data from relatives and non-relatives (71 vs 61%). These 
findings may be explained because most studies were 
normal in both groups (indeed, there are no “all positive” 
groups).
Although small, the difference in the results of the 
concordance of the colonic and the cardiac involvement 
in our study may reflect different tissue tropism of T. 
cruzi discrete typing units (DTU) and/or different dam-
age pathways for the digestive and the cardiologic form. 
On one hand, megaesophagus and megacolon are seen 
mainly in patients from the south cone of America and 
they have been related to specific pathogenicity of the 
DTU present in this area [29]. On the other hand, the 
pattern of the inflammatory infiltrates in the gastroin-
testinal tissue differ from those described in the cardiac 
form of chronic Chagas disease (inverse CD4/CD8 ratio, 
diminution of CD3+ and CD19+ cells) [30]. Indeed, 
the non-classical major histocompatibility class I chain-
related genes A and B (MICA and MICB) seem to rule 
the interaction of Tγδ, Tαβ CD8+ and natural killer cells 
with T. cruzi infesting the neuronal and muscular layers 
of hollow viscera [31]. The association of MICA*011 and 
HLA-B*14 and DRB1*01 could relate to megacolon [32].
The low rates of end-organ damage detected among 
the patients in our cohort may mask many differences 
between siblings and controls. These low rates may be 
explained because the vast majority of our diagnoses are 
screening tests of healthy individuals with a mean age of 
44 years old, and with female predominance, so they lack 
the classical risk factors for the development of the deter-
minate phase of chronic Chagas disease [33].
DTH
Our study does not show a higher concordance in DTH 
among siblings. Within those treated with benznidazole, 
DTH was registered in 17% of the relatives and in the 
20% of the non-relatives controls. In previous prospective 
studies and clinical trials DTH appeared in a 25–50% of 
the patients [6–9, 34]. This difference may be explained 
by the incomplete report of mild to moderate adverse 
events, and the large number of patients lost in the fol-
low up or who have not completed treatment because 
of adverse events different from skin reactions, or rea-
sons not related to toxicity in our retrospective cohort. 
Indeed, the incidence found in this study is similar to that 
reported of serious adverse events leading to treatment 
interruption, which are more likely to prompt medi-
cal assistance and therefore to be registered in clinical 
records.
Cutaneous DTH has been related to a delayed hyper-
sensitivity with a Th2 profile (with higher levels of IL-5, 
IL-10 and eosinophils). A previous study suggested 
an association between the presence of HLA-B*3505 
and moderate-to-severe DTH. This variant is relatively 
frequent among the Bolivian population [10]. Inter-
estingly, although not significant, when splitting con-
cordant groups into “all positives” and “all negatives”, a 
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bigger proportion of all negatives was found among sib-
ling groups (15 vs 4%). This finding may reflect a lower 
prevalence of HLA-B*3505 and other genetically deter-
mined toxicity risk factors.
It must be noted that the results of the aforementioned 
studies about the genetic determinants of end-organ 
damage in chronic Chagas disease have highly heteroge-
neous results, even between cohorts of patients from the 
same country. This is probably due to small sample sizes, 
lack of standardization in study methods (laboratory and 
statistical), ethnical variations and parasite variability [25, 
35–41]. The overall immune response against persistent 
T. cruzi infection is likely related to polygenic mecha-
nisms, as it depends on a complex cell and cytokine 
crosstalk [13, 24, 42–44], making it difficult to obtain 
valuable conclusions from the analysis of the relationship 
between a single genetic locus and a disease phenotype.
Certain limitations must be considered to contextualize 
the results of our study. First, as 94.11% of our patients 
came from Bolivia, our cohort had a highly homogene-
ous population, which may have masked the influence 
of familiar genetic background on clinical outcomes 
between siblings. Thus, our results may not be applicable 
to patients from underrepresented geographical origins. 
Similarly, as the origin of our patients was geographi-
cally narrow, they may have been infected with DTU with 
similar tissue tropism. Unfortunately, information about 
strain identification was not available in our cohort as it 
is not a part of our usual practice. Secondly, ambiental 
factors and re-infections are clear modifiers of the natural 
history of chronic Chagas disease [45]. In our cohort, re-
infections had been interrupted due to an improvement 
in vector control strategies in the countries of origin and 
to migration to an area where vector-borne transmission 
had not yet been reported. This could have induced a 
slower progression of organ damage, thus masking differ-
ent outcomes in this population.
Conclusions
We found a significantly higher proportion of concord-
ance in the result of pre-treatment PCR among Bolivian 
siblings. A non-significant trend was noted in barium 
enema results and the absence of DTH related to benzni-
dazole. Prospective studies with bigger sample sizes may 
be necessary to identify significant differences in end-
organ involvement of chronic Chagas disease.
Methods
Study design and availability of data
We performed a single-center retrospective study based 
on the database of patients who received the diagno-
sis of Chagas disease between 2002 and 2015 at the Vall 
dʼHebron University Hospital, a tertiary care center 
included in the International Health Program of Catalo-
nian Health Institute (Programa de Salut Internacional 
de l’Insitutt Catalá de Salut, PROSICS), in Barcelona, 
Spain (see Additional file 1: Table S1).
Data of 833 patients on the results of blood PCR for T. 
cruzi before treatment inception, the presence of organic 
damage (cardiac and/or gastrointestinal), and the pres-
ence of DTH in patients treated with benznidazole were 
reviewed. We identified groups of siblings and used the 
remaining patients of the database as controls, randomly 
generating non-related patient groups of 2 or 3 individu-
als in a ratio of 4:1 compared to groups of siblings. After 
the composition of these groups, we anonymized the data 
prior to analysis. We analyzed whether the variants were 
concordant or not in sibling groups and in the randomly-
generated non-sibling groups.
Clinical assessment
Chagas disease was diagnosed by means of two serologic 
tests: one based on recombinant antigen (Bioelisa Cha-
gas, Biokit, Lliçà d’Amunt, Spain) and the other based on 
crude antigen (Ortho T. cruzi ELISA, Johnson & Johnson, 
High Wycombe, UK) [46]. A polymerase chain-reaction 
(PCR) to detect T cruzi DNA in peripheral blood was 
performed in most patients according to the method 
described by Piron et al. [47].
At the time of the diagnosis, patients were evalu-
ated with a physical examination, an electrocardiogram 
(ECG), a chest x-ray and, if there was an abnormal result, 
cardiac ultrasound. Patients were classified according to 
the Kuschnir classification [48]. Gastrointestinal assess-
ment was based in symptoms present at initial evalua-
tion and barium radiographic imaging of esophagus and 
colon according to Rezende and Ximene’s classifications. 
Patients younger than 55 years were offered treatment 
with benznidazole. It must be noted that some patients 
were treated with posaconazole during a previous study 
[49]. Medication-related adverse events were registered 
prospectively. For statistical analysis, only cutaneous 
toxicity was considered as there is some evidence about 
genetic factors influencing this adverse event.
Statistical analysis
In each sibling and non-related randomly generated 
group we evaluated the result of the PCR (positive or 
negative), Kushnir (grade 0 vs 1 or higher), esophago-
gram (pathologic or normal), barium enema (patho-
logic or normal) and the presence of DTH within its 
members. The possible results were concordant, dis-
cordant or missing when data of one or more of the 
members of the group were not available. Those groups 
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in which data of the considered variable were missing 
in one or more of its members were excluded for statis-
tical analysis. Then we compared the difference in the 
proportions of concordance between the siblings and 
the control group using Fisher’s exact test and Pear-
son’s Chi-square test. We repeated the test splitting the 
concordant groups into “all positive” and “all negative”. 
All data were analyzed with Stata v.13.1 software and R 
v.3.5.1 software.
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Additional file 1: Table S1. The deidentified full dataset used in the 
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sets of siblings.
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